TBC1 domain family member 22AGenealiases: C22orf4 · HSC79E021
Q-omics provides the consensus-scored TBC1D22A profile across patient tissues and cancer cell-line models. TBC1D22A expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, TBC1D22A is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, TBC1D22A RNA expression shows 18,525 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SCLC, KIRC, and ACC as cancer lineages where TBC1D22A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TBC1D22A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TBC1D22A survival associations across molecular data types. TBC1D22A RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TBC1D22A RNA expression–survival associations across cancer types. High TBC1D22A expression shows unfavorable associations in OV, LIHC, ACC and UCS, but favorable associations in SCLC and ESCA. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for TBC1D22A RNA expression.
This table summarizes TBC1D22A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TBC1D22A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TBC1D22A shows lower tumor expression in THCA and UCEC and higher tumor expression in KIRC, LIHC, HNSC and CHOL. The KIRC box plot shows higher TBC1D22A RNA expression in tumor versus normal tissue (log2 FC = +0.633, t-test p < 0.001).
This table shows molecular features associated with TBC1D22A in patient tissues and cancer cell lines. In patient samples, TBC1D22A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TBC1D22A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
